These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 17919697)

  • 41. Central inhibition of refractory overactive bladder complaints, results of an inpatient training program.
    Meijer EF; Nieuwhof-Leppink AJ; Dekker-Vasse E; de Joode-Smink GC; de Jong TP
    J Pediatr Urol; 2015 Feb; 11(1):21.e1-5. PubMed ID: 25205144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of Transcutaneous Electrical Nerve Stimulation in the Management of Neurogenic Overactive Bladder: A Randomized Controlled Trial.
    Liu Y; Xu G; Geng J
    Am J Phys Med Rehabil; 2022 Jan; 101(1):2-10. PubMed ID: 34225282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of tamsulosin on systemic blood pressure and nonneurogenic dysfunctional voiding in children.
    Vanderbrink BA; Gitlin J; Toro S; Palmer LS
    J Urol; 2009 Feb; 181(2):817-22; discussion 822. PubMed ID: 19110267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transcutaneous neuromodulation for the urge syndrome in children: a pilot study.
    Hoebeke P; Van Laecke E; Everaert K; Renson C; De Paepe H; Raes A; Vande Walle J
    J Urol; 2001 Dec; 166(6):2416-9. PubMed ID: 11696801
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
    Klutke CG; Burgio KL; Wyman JF; Guan Z; Sun F; Berriman S; Bavendam T
    J Urol; 2009 Jun; 181(6):2599-607. PubMed ID: 19375110
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A pilot study of the home application of transcutaneous neuromodulation in children with urgency or urge incontinence.
    Bower WF; Moore KH; Adams RD
    J Urol; 2001 Dec; 166(6):2420-2. PubMed ID: 11696802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Percutaneous tibial nerve stimulation in treatment of overactive bladder: when should retreatment be started?
    Marchal C; Herrera B; Antuña F; Saez F; Perez J; Castillo E; Cantero J; Milla F; Machuca J; Redondo M; Galacho A
    Urology; 2011 Nov; 78(5):1046-50. PubMed ID: 21908024
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.
    Homma Y; Yamaguchi O
    Int J Urol; 2008 Oct; 15(11):986-91. PubMed ID: 18761536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
    Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transcutaneous sacral electrical stimulation versus oxibutynin for the treatment of overactive bladder in children.
    Casal-Beloy I; García-Novoa MA; García González M; Acea Nebril B; Somoza Argibay I
    J Pediatr Urol; 2021 Oct; 17(5):644.e1-644.e10. PubMed ID: 34176749
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A role of intravesical capsaicin instillation in benign prostatic hyperplasia with overactive bladder symptoms: the first reported study in the literature.
    Mahawong P; Chaiyaprasithi B; Soontrapa S; Tappayuthapijarn P
    J Med Assoc Thai; 2007 Nov; 90(11):2301-9. PubMed ID: 18181311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. At-home transcutaneous electrical nerve stimulation: a therapeutic alternative in the management of pediatric overactive bladder syndrome.
    Casal-Beloy I; Somoza Argibay I; García-González M; García-Novoa AM
    Cir Pediatr; 2020 Jan; 33(1):30-35. PubMed ID: 32166921
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Results of sacral posterior neuromodulation on voiding disorders and impact on sexuality based on a single-center study].
    Ferhi K; Miaadi N; Tanneau Y; Leroi AM; Sibert L; Grise P
    Prog Urol; 2008 Mar; 18(3):160-6. PubMed ID: 18472068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.